In guideline-recommended drug therapy management, SGLT2 inhibitors with proven benefits are recommended for patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease (Davies et al., 2018). The gene discussed is SLC5A2; the disease is chronic kidney disease.